Maurice Willis, MD
Medical Oncology · Saint Louis, MONPI 1942369319
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $66,806 of the $101,305 with a category attached, or 65.9%. Lilly USA, LLC accounts for 71.4% of it on its own, with 15 other manufacturers making up the rest. Among medical oncology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 119 payments — averaging $851.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$72K
- Tempus AI, Inc$10K
- Regeneron$5K
- Foundation Medicine, Inc.$5K
- Pfizer$2K
- AstraZeneca$2K
- plus $5K from 10 others
Across 25 payments — averaging $9241.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$59K
- AbbVie$50K
- Astrazeneca UK Limited$40K
- Eli Lilly$30K
- Genentech, Inc.$26K
- Merck Healthcare Kgaa$15K
- plus $11K from 1 others
What the payments were for
- Consulting fees$21,41121%
- Speaking & faculty fees$66,80666%
- Travel & lodging$9,4609%
- Food & beverage$3,5373%
- Education$890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 77 | $72,356 |
| Tempus AI, Inc | 10 | $9,582 |
| Regeneron | 4 | $5,245 |
| Foundation Medicine, Inc. | 4 | $4,805 |
| Pfizer | 1 | $2,200 |
| AstraZeneca | 4 | $1,883 |
| Novartis | 6 | $1,609 |
| Genentech USA, Inc. | 4 | $1,575 |
| G1 Therapeutics, Inc. | 1 | $1,500 |
| Genentech, Inc. | 2 | $241 |
| Recordati_rare_diseases_inc. | 1 | $82 |
| E.r. Squibb & Sons, L.L.C. | 1 | $78 |
| Ipsen Biopharmaceuticals, Inc | 1 | $64 |
| Gilead | 1 | $46 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Merck | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JAYPIRCA$17,427
- LIBTAYO$10,341
- FOUNDATIONACT$4,805
- FOUNDATIONFOCUS$4,805
- FOUNDATIONONE CDX$4,805
- FOUNDATIONONE HEME$4,805
- FOUNDATIONONE$4,805
- IMFINZI$1,665
- COSELA$1,500
- Alecensa$136
- Avastin$136
- Columvi$136
- Itovebi$136
- Lunsumio$136
- RETEVMO$117
- TECENTRIQ$106
How this compares
$101,305 in reported general payments places this provider in the 90th percentile of 144 medical oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 11 | $17,789 |
| Oxycodone Hcl | 63 | $1,087 |
| Prochlorperazine Maleate | 41 | $465 |
| Dexamethasone | 50 | $436 |
| Ondansetron Hcl | 52 | $419 |
| Olanzapine | 49 | $181 |
| Anastrozole | 33 | $120 |
| Prednisone | 19 | $89 |
| Pantoprazole Sodium | 12 | $31 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCOlanzapine | $72,356 | $18149 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 144 medical oncology providers in Missouri.
Other medical oncology in Saint Louis
- Brad KahlSaint Louis$336K
- Russell PachynskiSaint Louis$226K
- Mark SchroederSaint Louis$198K
- George AnsstasSaint Louis$189K
- Ravi VijSaint Louis$153K
- Douglas AdkinsSaint Louis$141K
- Milan ChhedaSaint Louis$105K
- Moh'd KhushmanSaint Louis$84K
- Camille AbboudSaint Louis$70K
- Bruce RothSaint Louis$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.